MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study

AIM: To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) versus ET alone in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) from China, Brazil, India, and South Af...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ther Adv Med Oncol
Hlavní autoři: Zhang, Qing Yuan, Sun, Tao, Yin, Yong Mei, Li, Hui Ping, Yan, Min, Tong, Zhong Sheng, Oppermann, Christina P., Liu, Yun Peng, Costa, Romulo, Li, Man, Cheng, Ying, Ouyang, Qu Chang, Chen, Xi, Liao, Ning, Wu, Xin Hong, Wang, Xiao Jia, Feng, Ji Feng, Hegg, Roberto, Kanakasetty, G.B., Coccia-Portugal, Maria A., Han, Ru Bing, Lu, Yi, Chi, Hai Dong, Jiang, Ze Fei, Hu, Xi Chun
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7586037/
https://ncbi.nlm.nih.gov/pubmed/33149768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920963925
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky